Krr Drugs And Chemicals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 5.78 Cr
as on 24-10-2024
- Company Age 20 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 9.07 Cr
as on 24-10-2024
- Revenue %
(FY 2023)
- Profit 42.23%
(FY 2023)
- Ebitda 60.02%
(FY 2023)
- Net Worth -3.33%
(FY 2023)
- Total Assets -3.33%
(FY 2023)
About Krr Drugs And Chemicals
The Corporate was formerly known as Indira Dairy Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.78 Cr.
The company has closed loans amounting to ₹9.07 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Venkata Raju and Murali Vadlamudi serve as directors at the Company.
- CIN/LLPIN
U24100TG2004PTC044765
- Company No.
044765
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Krr Drugs And Chemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murali Vadlamudi  | Managing Director | 04-Jun-2015 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Raju | Director | 04-Jun-2015 | Current |
Financial Performance of Krr Drugs And Chemicals.
Krr Drugs And Chemicals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 42.23% increase in profit. The company's net worth dipped by a decrease of 3.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krr Drugs And Chemicals?
In 2023, Krr Drugs And Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Jun 2015 | ₹7.40 Cr | Satisfied |
Syndicate Bank Creation Date: 19 Mar 2008 | ₹3.82 M | Satisfied |
Syndicate Bank Creation Date: 20 Feb 2008 | ₹8.50 M | Satisfied |
How Many Employees Work at Krr Drugs And Chemicals?
Unlock and access historical data on people associated with Krr Drugs And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krr Drugs And Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krr Drugs And Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
